两性霉素B次优剂量联合伏立康唑在对唑类药物反应不佳的烟曲霉感染小鼠模型中的疗效
Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor Response to the Azole.
作者信息
Sandoval-Denis Marcelo, Pastor F Javier, Capilla Javier, Guarro Josep
机构信息
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain.
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain
出版信息
Antimicrob Agents Chemother. 2013 Sep;57(9):4540-4542. doi: 10.1128/AAC.00563-13. Epub 2013 Jun 24.
Abstract
The combination of amphotericin B at a suboptimal dose (0.3 mg/kg) with voriconazole has shown efficacy in prolonging survival and reducing tissue burden in a murine model of disseminated infection by an isolate of that had showed a poor response to the azole. The efficacy of the combined treatment was higher than that obtained with amphotericin B at 0.8 mg/kg.
摘要
在一种小鼠播散性感染模型中，次优剂量（0.3mg/kg）的两性霉素B与伏立康唑联合使用，对于一种对唑类药物反应不佳的分离株显示出延长生存期和减轻组织负荷的效果。联合治疗的疗效高于0.8mg/kg两性霉素B的疗效。
相似文献
1
Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor Response to the Azole.两性霉素B次优剂量联合伏立康唑在对唑类药物反应不佳的烟曲霉感染小鼠模型中的疗效
Antimicrob Agents Chemother. 2013 Sep;57(9):4540-4542. doi: 10.1128/AAC.00563-13. Epub 2013 Jun 24.
2
Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.脂质体两性霉素B在两种不同免疫抑制侵袭性曲霉病模型中对野生型和唑类耐药烟曲霉分离株的疗效。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02479-16. Print 2017 Jun.
3
Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B.脑型耐唑类烟曲霉感染的管理：脑室内脂质体两性霉素B的作用
J Glob Antimicrob Resist. 2020 Sep;22:354-357. doi: 10.1016/j.jgar.2020.03.016. Epub 2020 Apr 3.
4
Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.使用体外药代动力学-药效学模型优化抗曲霉病的多烯-唑联合疗法。
Antimicrob Agents Chemother. 2015 Jul;59(7):3973-83. doi: 10.1128/AAC.05035-14. Epub 2015 Apr 20.
5
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.脂质体两性霉素 B 对不同唑类耐药烟曲霉分离株在播散性曲霉病小鼠模型中的药效学和剂量反应关系。
Antimicrob Agents Chemother. 2013 Apr;57(4):1866-71. doi: 10.1128/AAC.02226-12. Epub 2013 Feb 4.
6
Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.评估抗真菌药物对烟曲霉的疗效：实时生物发光成像的价值。
Antimicrob Agents Chemother. 2013 Jul;57(7):3046-59. doi: 10.1128/AAC.01660-12. Epub 2013 Apr 15.
7
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.传统两性霉素B、脂质体两性霉素B（安必素）、卡泊芬净、米卡芬净和伏立康唑单独及联合应用对实验性小鼠中枢神经系统曲霉病的疗效比较
Antimicrob Agents Chemother. 2005 Dec;49(12):4867-75. doi: 10.1128/AAC.49.12.4867-4875.2005.
8
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).曲霉属临床分离株及实验室筛选的耐药菌株对两性霉素B、伊曲康唑、伏立康唑和泊沙康唑（SCH 56592）体外敏感性的比较研究
J Antimicrob Chemother. 2000 Aug;46(2):229-34. doi: 10.1093/jac/46.2.229.
9
Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.非中性粒细胞减少症侵袭性曲霉菌病小鼠模型中评价阿尼芬净对临床烟曲霉分离株的药效动力学。
Antimicrob Agents Chemother. 2013 Jan;57(1):303-8. doi: 10.1128/AAC.01430-12. Epub 2012 Oct 31.
10
Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.烟曲霉伏立康唑耐药实验室分离株对两性霉素B、伊曲康唑和泊沙康唑的体外分离及敏感性
Clin Microbiol Infect. 2001 Mar;7(3):130-7. doi: 10.1046/j.1469-0691.2001.00220.x.
引用本文的文献
1
[Combination antifungal therapy for invasive fungal disease in children with hematologic disease].[血液系统疾病患儿侵袭性真菌病的联合抗真菌治疗]
Zhonghua Xue Ye Xue Za Zhi. 2015 Nov;36(11):912-7. doi: 10.3760/cma.j.issn.0253-2727.2015.11.005.
2
In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.两性霉素B与泊沙康唑在小鼠曲霉病中的体内协同作用
Antimicrob Agents Chemother. 2015 Oct 26;60(1):296-300. doi: 10.1128/AAC.01462-15. Print 2016 Jan.
3
Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.使用体外药代动力学-药效学模型优化抗曲霉病的多烯-唑联合疗法。
Antimicrob Agents Chemother. 2015 Jul;59(7):3973-83. doi: 10.1128/AAC.05035-14. Epub 2015 Apr 20.
4
Successful treatment of Paecilomyces variotii peritonitis in a liver transplant patient.成功治疗肝移植患者烟曲霉腹膜炎。
Mycopathologia. 2015 Apr;179(3-4):317-20. doi: 10.1007/s11046-014-9854-1. Epub 2014 Dec 23.
5
In vitro combination of voriconazole and miltefosine against clinically relevant molds.伏立康唑与米替福新针对临床相关霉菌的体外联合应用
Antimicrob Agents Chemother. 2014 Nov;58(11):6996-8. doi: 10.1128/AAC.03212-14. Epub 2014 Sep 8.
本文引用的文献
1
Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.评估伏立康唑的体外活性对烟曲霉感染模型中体内结果的预测价值。
Antimicrob Agents Chemother. 2013 Mar;57(3):1404-8. doi: 10.1128/AAC.01331-12. Epub 2013 Jan 7.
2
Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.960 例侵袭性曲霉菌病患者的临床流行病学分析：PATH 联盟注册研究。
J Infect. 2012 Nov;65(5):453-64. doi: 10.1016/j.jinf.2012.08.003. Epub 2012 Aug 13.
3
In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.烟曲霉中由于 G448S 突变（cyp51A 基因）导致伏立康唑耐药的体外-体内相关性。
Diagn Microbiol Infect Dis. 2012 Nov;74(3):272-7. doi: 10.1016/j.diagmicrobio.2012.06.030. Epub 2012 Aug 14.
4
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis.移植患者侵袭性曲霉菌感染的抗真菌治疗与住院时间。
Med Mycol. 2013 Feb;51(2):128-35. doi: 10.3109/13693786.2012.690108. Epub 2012 Jun 11.
5
Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis.比较高剂量氟康唑、伏立康唑和氟胞嘧啶作为二线药物联合两性霉素 B 治疗 HIV 相关隐球菌性脑膜炎的早期杀菌活性。
Clin Infect Dis. 2012 Jan 1;54(1):121-8. doi: 10.1093/cid/cir745. Epub 2011 Nov 3.
6
Combination antifungal therapy for invasive pulmonary aspergillosis in a heart transplant recipient.心脏移植受者侵袭性肺曲霉病的联合抗真菌治疗
Exp Clin Transplant. 2011 Aug;9(4):279-83.
7
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.在侵袭性肺曲霉病的小鼠模型中进行的治疗和毒理学研究。
Med Mycol. 2011 Nov;49(8):834-47. doi: 10.3109/13693786.2011.577822. Epub 2011 May 4.
8
Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature.根据基础疾病的侵袭性曲霉菌病的流行病学和抗真菌耐药性：文献复习。
Eur J Med Res. 2011 Apr 28;16(4):153-7. doi: 10.1186/2047-783x-16-4-153.
9
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.利用流行病学截断值研究 9 年来 Aspergillus 属对三唑类药物敏感性的变化趋势。
J Clin Microbiol. 2011 Feb;49(2):586-90. doi: 10.1128/JCM.02136-10. Epub 2010 Dec 1.
10
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中三唑类药物和六种曲霉菌属的野生型 MIC 分布和流行病学折点值。
J Clin Microbiol. 2010 Sep;48(9):3251-7. doi: 10.1128/JCM.00536-10. Epub 2010 Jun 30.
Zotero 插件